ArticleLeukemia2026

Phase I, open-label, multi-center dose-finding and expansion study to investigate the safety, tolerability, and preliminary efficacy of CR-001 (5-FU-miR-15a) in patients with acute myeloid leukemia.

Irini Ktoridou-Valen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.